OTC:FOSUY

Citi, UBS, GS view positive on Fosun's core business-focused strategy

Retrieved on: 
Tuesday, April 23, 2024
Goldman Sachs, HKEX, Fosun Pharma, GS, BCP, Research, UBS, Fosun International, Happiness, Research report, Growth

Goldman Sachs gave Fosun International a target price of HK$4.90, representing an upside of over 13%.

Key Points: 
  • Goldman Sachs gave Fosun International a target price of HK$4.90, representing an upside of over 13%.
  • Fosun International's businesses in Health, Happiness and Wealth segments are expected to keep on growing steadily in the future.
  • Citi Research also issued a report in which it expressed its optimistic views about Fosun International's market outlook.
  • Citi Research gave Fosun a "Buy" rating, with a target price of HK$ 6.30, an expected increase of approximately 57%.

Fosun's Next Step: "Deep Mining" for Stable Profits

Retrieved on: 
Thursday, March 28, 2024
Cell, World Health Organization, NMPA, Club Med, Growth, DLBC, Fashion Group International, Mining, KOD, Breast cancer, Gene, National Medical Products Administration, Tourism, Snow, Happiness, Leonardo da Vinci, HKEX, SCLC, Research, Marketing, Fosun Pharma, Lithium, Ice, FTG, Carcinoma, European, Patient, Artesunate, Letter, COVID-19, Fine chemical

With the implementation of the business streamlining strategy, Fosun divested some non-core businesses that had previously provided stable cash flows.

Key Points: 
  • With the implementation of the business streamlining strategy, Fosun divested some non-core businesses that had previously provided stable cash flows.
  • The subsequent improvement in cash flow has brought market attention to how Fosun will sustain stable profit growth as it did over the past decade.
  • The results announcement shows that Fosun's focus on its core businesses in the household consumption sector has gradually yielded results.
  • Leveraging on the two core growth drivers of innovation and globalization, Fosun has continued to deepen its efforts in advantageous industries and reap more stable profits.

Fosun successfully completed the refinancing of approximately USD800 million loan

Retrieved on: 
Friday, May 10, 2024
Fosun International, Bank of China, Commerzbank, BNP Paribas, Standard Chartered, HSBC, QNB Group, HKEX, Hang Seng Bank, Bank, Bank of East Asia

HONG KONG, May 9, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International", "Fosun" or "the Company") has successfully completed the refinancing of its USD804 million loan due on 7 May 2024.

Key Points: 
  • HONG KONG, May 9, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International", "Fosun" or "the Company") has successfully completed the refinancing of its USD804 million loan due on 7 May 2024.
  • As part of the refinancing process, the Company has successfully obtained a new syndicate loan of USD597 million, while the remaining was repaid through its own funds.
  • Fosun has established diversified financing channels, well-recognized financing capabilities and prudent financial policies, and has been proactively managing its debt duration and yield curve.
  • Looking ahead, Fosun will continue to implement its core business-focused strategy and improve its operating capabilities in advantageous industries.

FOSUN FOR GOOD, CREATING IMPACT: Fosun International Issued its 2023 ESG Report and the Second Climate Information Disclosures Report

Retrieved on: 
Friday, April 26, 2024
Carbon, Carbon neutrality, Education, World Health Organization, NMPA, Malaria, HSI, Risk management, Culture, CSA, United Nations Global Compact, Climate, Disclosure, National Medical Products Administration, Sustainability, Create, Task force, Climate change, HKEX, Ecosystem, Health, SCLC, Biophysical environment, Temperature, AA, Cancer, Social, Hope, Policy, Paris Agreement, MSCI, Environment, Patient, Artesunate, ESG, The Bund Finance Center, Renewable energy

HONG KONG , April 26, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today issued the Environmental, Social and Governance (ESG) Report 2023 (the "ESG Report").

Key Points: 
  • HONG KONG , April 26, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today issued the Environmental, Social and Governance (ESG) Report 2023 (the "ESG Report").
  • Facing the increasingly severe challenges of global climate change, Fosun released its second Climate Information Disclosures Report with reference to the disclosure requirements of the Hong Kong Stock Exchange, the Task Force on Climate-Related Financial Disclosures ("TCFD") recommendations and IFRS S2 Climate-related Disclosures.
  • This year, the Group has actively pursued its carbon neutrality goal and issued the second Climate Information Disclosures Report.
  • For more information on Fosun's ESG, please refer to Fosun International's ESG Report 2023 posted on:
    The electronic copy of the 2023 Climate Information Disclosures Report is available on the Company's ESG webpage: ( https://en.fosun.com/esg/ )

Fosun's Subsidiary Fidelidade Announces Listing Plan of Private Health Service Company Luz Saúde

Retrieved on: 
Thursday, April 11, 2024
CMVM, Sale, Prospectus, Hospital, Bed, Accounting, Nursing, Patient, Growth, Euronext Lisbon

If realized, this operation will create better conditions for the continued expansion and growth of Luz Saúde in the health sector.

Key Points: 
  • If realized, this operation will create better conditions for the continued expansion and growth of Luz Saúde in the health sector.
  • Luz Saúde is recognized as a leading private health service provider in Portugal, noted for the quality and innovation of its approach.
  • After the public offering, Fidelidade intends to retain the majority of the share capital of Luz Saúde.
  • Fosun stated that Luz Saúde's listing plan marks an important milestone for both Luz Saúde and Fidelidade in the health sector, which will benefit the development of Fosun's Health segment and enhance Luz Saúde's corporate governance, and provide Luz Saúde an independent fundraising platform.

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

Retrieved on: 
Tuesday, April 2, 2024
Gene, Artesunate, NMPA, Fosun International, Growth, Cell, Carcinoma, Patient, MSCI, FTG, Rehabilitation, Fosun Pharma, World Health Organization, National Medical Products Administration, Club Med, HKEX, Sustainability, Marketing, SCLC, HSI, AA

During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.

Key Points: 
  • During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.
  • Industrial operation profit reached RMB4.9 billion, representing a year-on-year increase of 20%.
  • Total revenue of the four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (FTG), was RMB142.69 billion, representing a year-on-year increase of 8%, contributing 72% of the revenue.
  • In 2023, Fosun's overseas revenue reached RMB89.2 billion, representing a year-on-year growth of 6% and accounting for 45% of the total revenue.

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

Retrieved on: 
Tuesday, April 2, 2024
Gene, Artesunate, NMPA, Fosun International, Growth, Cell, Carcinoma, Patient, MSCI, FTG, Rehabilitation, Fosun Pharma, World Health Organization, National Medical Products Administration, Club Med, HKEX, Sustainability, Marketing, SCLC, HSI, AA

During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.

Key Points: 
  • During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.
  • Industrial operation profit reached RMB4.9 billion, representing a year-on-year increase of 20%.
  • Total revenue of the four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (FTG), was RMB142.69 billion, representing a year-on-year increase of 8%, contributing 72% of the revenue.
  • In 2023, Fosun's overseas revenue reached RMB89.2 billion, representing a year-on-year growth of 6% and accounting for 45% of the total revenue.